EUCTR2018-000318-39-GB进行中（未招募）1 期
A phase II trial assessing nivolumab in strong class II expressing microsatellite stable colorectal cancer - ANICCA-Class II
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 36
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •Histologically confirmed locally advanced or metastatic MSS CRC with strong class II expression (greater than 50% cancer cell positivity for class II expression on immunohistochemistry).
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •Age = 18 years
- •Patients must have completed all standard of care therapy that the treating oncologist deems appropriate. Trial treatment as first line therapy is permitted if the patient has declined standard of care therapy.
- •CT scan of chest, abdomen, pelvis within 28 days of registration demonstrating uni-dimensionally measurable disease as per RECIST version 1.1
- •Demonstrate adequate haematological function:
- •oPlatelet count =100 x 109 /L
- •oNeutrophils =1.5 x 109/L
- •oHaemoglobin = 90 g/L
- •Demonstrate adequate hepatic function:
- •oSerum bilirubin =1.5 x upper limit of normal (ULN)
- •oSerum AST or ALT =2.5 x ULN or <5 x ULN in the presence of liver metastases
- •Demonstrate adequate renal function
- •oCreatinine clearance <1.5 times ULN and >30ml/min (as per institutional standard).
- •Provision of signed and dated, written informed consent prior to any trial specific procedures, sampling and analyses.
- •Negative pregnancy test (female patients of reproductive potential).
- •Patients must agree to the use of contraception
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •Previous treatment with PD1/PDL1 inhibitors.
- •Untreated symptomatic brain or leptomeningeal metastatic disease.
- •Medical or psychiatric conditions compromising informed consent.
- •Any medical condition which, in the opinion of the Investigator, would compromise the ability of the patient to participate in the trial or which would jeopardise compliance with the protocol.
- •Administration of chemotherapy, radioactive or biological cancer therapy within 4 weeks prior to the first dose of trial therapy
- •Patient has not recovered to CTCAE grade 1 or better from the Adverse Event (AE) due to cancer therapeutics administered more than 4 weeks earlier.
- •Active autoimmune disease that has required systemic treatment in past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.
- •Patient has risk factors for bowel obstruction or bowel perforation (examples include but not limited to a history of acute diverticulitis, intra-abdominal abscess and abdominal carcinomatosis).
- •Patient has a known history of other malignancy, unless the patient has undergone potentially curative therapy with no evidence of that disease for 3 years.
- •Has a history of non-infectious pneumonitis requiring steroids or has active neumonitis or significantly reduced transfer coefficient (KCO).
- •Female patients that are either pregnant or breast feeding.
- •Male and female patients (of childbearing age) not willing to use adequate contraception.
- •Patient previously had a severe hypersensitivity reaction to treatment with another monoclonal antibody.
- •Patient is positive for Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies), active Hepatitis B (HBsAg reactive) or Hepatitis C (HCV RNA (qualitative) is detected); patients with negative Hepatitis C antibody testing may not need RNA testing.
- •Known history of tuberculosis.
- •Patient has an active infection requiring therapy.
- •Has received a live vaccine within 30 days prior to the first dose of trial treatment.
- •Patient is, at the time of signing informed consent, a regular user (including recreational use”) of any illicit drugs or had a recent history (within the last year) of substance abuse (including alcohol).
研究者
相似试验
进行中（未招募）
1 期
A randomised phase II trial comparing two different ways of combining nivolumab and ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma.Previously untreated metastatic clear cell renal cell carcinoma.MedDRA version: 20.0Level: PTClassification code 10050513Term: Metastatic renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10067946Term: Renal cell carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2017-001476-33-GBniversity of Leeds189
进行中（未招募）
1 期
A study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with Hodgkin LymphomaEUCTR2017-001939-38-FRYSARC64
进行中（未招募）
1 期
A study of nivolumab alone, or in combination with vinblastin in patients aged 61 years and older, with Hodgkin Lymphomapatients aged 61 years and older, with classical Hodgkin lymphoma and coexisting medical conditionsMedDRA version: 20.1Level: LLTClassification code 10080208Term: Classical Hodgkin lymphomaSystem Organ Class: 100000004864EUCTR2017-001939-38-BEYSARC64
进行中（未招募）
2 期
A phase II trial to find the durable clinical benefit of nivolumab in class II expressing microsatellite colorectal cancerColorectal cancerCancerISRCTN40245896niversity of Birmingham36
进行中（未招募）
1 期
A randomized, run-in, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/PD-L1MM and NSCLC patients resistant to anti-PD-1/PD-L1 therapyMedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2019-002986-36-ITFONDAZIONE NIBIT NETWORK ITALIANO PER LA BIOTERAPIA DEI TUMORI184